N-(2,3-di-hexadecyloxy)-prop-1-yl-N,N,N-trimethylammonium chloride | 138797-39-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(2,3-di-hexadecyloxy)-prop-1-yl-N,N,N-trimethylammonium chloride
• 英文别名: Bishop；2,3-dihexadecoxypropyl(trimethyl)azanium;chloride
• CAS: 138797-39-4
• 化学式: C₃₈H₈₀NO₂*Cl
• 分子量: 618.512
• InChiKey: RLKJVRDMIQCNGX-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  9.06
• 重原子数：
  42
• 可旋转键数：
  35
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Pharmaceutical formulation of nicardipine and 1,2-dioxy-omega-trialkylammonium compounds
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0188311A2

  公开（公告）日：1986-07-23

  This invention relates to a pharmaceutical formulation comprising nicardipine hydrochloride and N-(ω,ω-1- dialkoxy)- and N-(ω,ω-1-dialkenoxy)- alk-1-yl-N,N,N-trisubstituted ammonium surfactants.

  本发明涉及一种药物制剂，包含盐酸尼卡地平和 N-(ω,ω-1-二烷氧基)-和 N-(ω,ω-1-二烯氧基)-烷-1-基-N,N,N-三取代铵表面活性剂。
• Stable liposomes with aqueous-soluble medicaments and methods for their preparation
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0172007B1

  公开（公告）日：1991-05-22
• N-(omega,omega-1-dialkoxy)- and N-(omega,omega-1-dialkenoxy)-alk-1-yl-N,N,N-trisubstituted ammonium surfactants, their preparation and pharmaceutical formulations containing them
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0187702B1

  公开（公告）日：1990-03-14
• GENE THERAPY DELIVERY SYSTEM FOR TARGETING TO ENDOTHELIA
  申请人：West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited

  公开号：EP0986404B1

  公开（公告）日：2002-04-17
• COMPOSITIONS AND METHODS FOR NUCLEIC ACID DELIVERY
  申请人：Boyce Frederick M.

  公开号：US20110111459A1

  公开（公告）日：2011-05-12

  Disclosed herein are methods and compositions for preparing a lipid encapsulated nucleocapsid delivery composition capable of delivering a nucleic acid to a mammalian cell. The nucleocapsid delivery compositions disclosed herein are useful for large-scale protein production, expression of genes in a mammalian expression system, and/or pharmaceutical production of a recombinant protein for treatment of an individual. In addition, the nucleocapsid delivery compositions can be used to treat an individual to replace a gene or gene product, or alternatively to inhibit a gene product using an RNA interference molecule.